Normal Donor Blood Draws for Platelet Studies and Biomarker Evaluation (ND-PLT)
ND-PLT
2 other identifiers
observational
400
1 country
1
Brief Summary
This is a single-center study at the Cleveland Clinic Main Campus designed to study biomarkers in healthy individuals to identify novel mechanisms of platelet activation and how platelets drive vascular inflammation and thrombosis in diseases.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started May 2020
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 1, 2020
CompletedFirst Submitted
Initial submission to the registry
November 16, 2022
CompletedFirst Posted
Study publicly available on registry
November 29, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2030
ExpectedStudy Completion
Last participant's last visit for all outcomes
June 30, 2031
December 16, 2025
December 1, 2025
10.7 years
November 16, 2022
December 15, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
To collect blood samples
To establish a biorepository for normal healthy cohort of subjects
10 years
Eligibility Criteria
Voluntary donors will be screened by questioning for use of anti-coagulant medications such as aspirin or other non-steroidal anti-inflammatory agents, in the past 10 days, or for hematopoietic diseases. Only healthy volunteers included as platelet donors.
You may qualify if:
- Adults aged 18 to 65 years old
- Healthy Male \& Female voluntary participants
You may not qualify if:
- Individuals who have taken anticoagulant or antiplatelet medications in past 10 days
- Individuals with hematopoetic diseases
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Cleveland Clinic
Cleveland, Ohio, 44195, United States
Related Publications (4)
Cameron SJ, Ture SK, Mickelsen D, Chakrabarti E, Modjeski KL, McNitt S, Seaberry M, Field DJ, Le NT, Abe J, Morrell CN. Platelet Extracellular Regulated Protein Kinase 5 Is a Redox Switch and Triggers Maladaptive Platelet Responses and Myocardial Infarct Expansion. Circulation. 2015 Jul 7;132(1):47-58. doi: 10.1161/CIRCULATIONAHA.115.015656. Epub 2015 May 1.
PMID: 25934838BACKGROUNDSchmidt RA, Morrell CN, Ling FS, Simlote P, Fernandez G, Rich DQ, Adler D, Gervase J, Cameron SJ. The platelet phenotype in patients with ST-segment elevation myocardial infarction is different from non-ST-segment elevation myocardial infarction. Transl Res. 2018 May;195:1-12. doi: 10.1016/j.trsl.2017.11.006. Epub 2017 Dec 2.
PMID: 29274308BACKGROUNDHilt ZT, Pariser DN, Ture SK, Mohan A, Quijada P, Asante AA, Cameron SJ, Sterling JA, Merkel AR, Johanson AL, Jenkins JL, Small EM, McGrath KE, Palis J, Elliott MR, Morrell CN. Platelet-derived beta2M regulates monocyte inflammatory responses. JCI Insight. 2019 Mar 7;4(5):e122943. doi: 10.1172/jci.insight.122943. eCollection 2019 Mar 7.
PMID: 30702442BACKGROUNDFaraday N, Goldschmidt-Clermont PJ, Bray PF. Gender differences in platelet GPIIb-IIIa activation. Thromb Haemost. 1997 Apr;77(4):748-54.
PMID: 9134654BACKGROUND
Biospecimen
Blood
Study Officials
- PRINCIPAL INVESTIGATOR
Scott Cameron, MD, PhD
The Cleveland Clinic
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
November 16, 2022
First Posted
November 29, 2022
Study Start
May 1, 2020
Primary Completion (Estimated)
December 31, 2030
Study Completion (Estimated)
June 30, 2031
Last Updated
December 16, 2025
Record last verified: 2025-12
Data Sharing
- IPD Sharing
- Will not share